On July 27, 2017 Proteros biostructures GmbH reported that the company has entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on a sub-class of epigenetic targets (Press release, proteros biostructures, JUL 27, 2017, View Source;tx_news_pi1%5Baction%5D=detail&cHash=a38b6bfffb6b6cbdbafc7a8a11ea05f0 [SID1234519912]). The deal was facilitated by Johnson & Johnson Innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new collaboration agreement is focused on the discovery of novel lead compounds against several epigenetic targets for various cancer indications. Under the agreement, Janssen gains access to Proteros’ proprietary Nucleosomal Epigenetic Assay Technology (NEATTM) and discovery platform aimed at technically complex targets to identify quality lead compounds. Janssen has the option to license the lead compounds for further development and commercialization or the parties may jointly further develop and partner.

Financial terms of the collaboration were not disclosed.

Dr. Torsten Neuefeind, CEO of Proteros commented: "We are pleased to be working with Janssen to address a set of novel and complex epigenetic targets to create oncology drugs. We believe that the structure of the collaboration will accelerate the discovery of novel therapies and maximize the value generation for both parties."